Everlywell, the US-based medical test provider backed by over-the-top media company The Chernin Group, has received $75m in funding from venture capital firm HealthQuest Capital, TechCrunch has reported.
Founded in 2015, Everlywell offers a range of at-home testing kits for conditions such as covid-19, lyme disease and sexually transmitted infections in addition to those testing food allergies and sensitivities or cholesterol, vitamin D or testosterone levels.
The capital was supplied at the same $1.3bn valuation at which Everlywell last raised money and will be used to provide liquidity to its existing investors. Garheng Kong, founder and managing partner of HealthQuest Capital, is joining its board of directors.
Chernin Group took part in the previous round, a $175m series D last month that included Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures, Portfolia, Goodwater Capital, Highland Capital Partners, Next Coast Ventures and funds and accounts managed by BlackRock.
Highland Capital, Goodwater Capital, Next Coast Ventures and NextGen Venture Partners had previously provided $50m in series C funding for the company in 2019. Its total funding now stands at about $325m.
Photo courtesy of Everlywell, Inc.
